Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 20/20 | 0.74 |
| ▸ | FLT3 | P36888 | 18/20 | 0.74 |
| ▸ | KIT | P10721 | 17/20 | 0.74 |
| ▸ | CSF1R | P07333 | 7/20 | 0.63 |
| ▸ | FLT1 | P17948 | 7/20 | 0.63 |
| ▸ | LCK | P06239 | 4/20 | 0.63 |
| ▸ | FLT4 | P35916 | 4/20 | 0.63 |
| ▸ | FYN | P06241 | 3/20 | 0.63 |
| ▸ | LYN | P07948 | 3/20 | 0.63 |
| ▸ | BLK | P51451 | 3/20 | 0.63 |
| ▸ | SRC | P12931 | 2/20 | 0.63 |
| ▸ | ABL1 | P00519 | 1/20 | 0.63 |
| ▸ | AURKA | O14965 | 3/20 | 0.63 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.63 |
| ▸ | RPS6KA5 | O75582 | 3/20 | 0.63 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.63 |
| ▸ | RET | P07949 | 3/20 | 0.63 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.63 |
| ▸ | FER | P16591 | 3/20 | 0.63 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL425756 | 0.90 | KDR (0.73) | KDRFLT3KITCSF1RFLT1 | |
| SCHEMBL419979 | 0.90 | KDR (0.70) | KDRFLT3KITCSF1RFLT1 | |
| SCHEMBL421843 | 0.90 | KDR (0.79) | KDRFLT3KITCSF1RFLT1 | |
| SCHEMBL421195 | 0.90 | KDR (0.71) | KDRFLT3KITCSF1RFLT1 | |
| SCHEMBL422104 | 0.90 | KDR (0.78) | KDRFLT3KITCSF1RFLT1 | |
| SCHEMBL423515 | 0.90 | KDR (0.78) | KDRFLT3KITCSF1RFLT1 | |
| SCHEMBL421368 | 0.89 | KDR (0.77) | KDRFLT3KITCSF1RFLT1 | |
| SCHEMBL421811 | 0.88 | KDR (0.74) | KDRFLT3KITCSF1RFLT1 | |
| SCHEMBL419413 | 0.88 | KDR (0.81) | KDRFLT3KITCSF1RFLT1 | |
| SCHEMBL422768 | 0.88 | KDR (0.62) | KDRFLT3KITCSF1RFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130245015-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBVIE INC (US) | 2013-09-19 | — | — | US | claimed |
| EP-2246333-B1 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBOTT LAB (US) | 2012-10-24 | — | — | EP | claimed |
| EP-2246333-A1 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | Abbott Laboratories (US) | 2010-11-03 | — | — | EP | claimed |
| US-7598283-B2 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBOTT LABORATORIES, INC. (US) | 2009-10-06 | — | — | US | claimed |
| US-20090105245-A1 | METHODS FOR TREATING MACULAR EDEMA AND OCULAR ANGIOGENESIS USING AN ANTI-INFLAMMATORY AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR | NOVARTIS AG (CH) | 2009-04-23 | — | — | US | claimed |
| US-20080153819-A1 | METHODS FOR TREATING MACULAR EDEMA AND PATHOLOGIC OCULAR ANGIOGENESIS USING A NEUROPROTECTIVE AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR | NOVARTIS AG (CH) | 2008-06-26 | — | — | US | claimed |
| US-20080153818-A1 | preventing inflammation and retinal edema resulting from an ocular surgical procedure by administering to a patient undergoing surgery a therapeutically effective amount of a composition comprising an active agent selected from the group consisting of RTK inhibitors and anti-VEGF compounds | ALCON, INC. (CH) | 2008-06-26 | — | — | US | claimed |
| US-20080076767-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBVIE INC. | 2008-03-27 | — | — | US | claimed |
| EP-1850839-A2 | METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS | ALCON INC. (CH) | 2007-11-07 | — | — | EP | claimed |
| WO-2006091801-A2 | METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS | ALCON, INC. (CH) | 2006-08-31 | — | — | WO | claimed |
| US-20060189608-A1 | Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors | ALCON, INC. | 2006-08-24 | — | — | US | claimed |
| US-20050020603-A1 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBVIE INC. | 2005-01-27 | — | — | US | claimed |
| US-8940778-B2 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBVIE INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8642776-B2 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBVIE INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130245015-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBVIE INC (US) | 2013-09-19 | — | — | US | disclosed |
| EP-2594264-A1 | Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective rtk inhibitors | Novartis AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| US-20060189608-A1 | Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors | ALCON, INC. | 2006-08-24 | — | — | US | disclosed |
| EP-1638941-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20050020603-A1 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBVIE INC. | 2005-01-27 | — | — | US | disclosed |
| WO-2004113304-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245015-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABL1, BLK, BTK | KDR 724/4885FLT3 41/4885KIT 361/4885 |
| US-20080076767-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABL1, BLK, BTK | KDR 724/4885FLT3 41/4885KIT 361/4885 |
| US-20090105245-A1 | METHODS FOR TREATING MACULAR EDEMA AND OCULAR ANGIOGENESIS USING AN ANTI-INFLAMMATORY AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR | FLT1, TEK, FLT4 | KDR 4/4885FLT3 165/4885KIT 70/4885 |
| US-20050020603-A1 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABL1, BLK, BTK | KDR 724/4885FLT3 41/4885KIT 361/4885 |
| US-20060189608-A1 | Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors | KDR, FLT4, FLT1 | KDR 1/4885FLT3 34/4885KIT 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.